We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAAS:TSXPan American Silver Corp. Analysis

Data as of 2026-05-13 - not real-time

CA$87.42

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Pan American Silver delivered a blockbuster Q1 2026, posting $1.15 billion in revenue (up 49.3% YoY) and $457 million net income, with EPS of $1.08 beating the prior‑year $0.42. The results spurred a 12% one‑day price jump, lifting the share price to $87.42, comfortably above the 20‑day ($76.5) and 50‑day ($76.5) SMAs and approaching the 30‑day resistance of $88.04. Technicals are supportive: the RSI sits at 68, the MACD histogram is positive (1.58) and the signal line is bearish, yielding a bullish MACD stance. Volume is increasing, indicating growing participation.
The stock appears undervalued, with a DCF fair value of $114.16 and an upside of roughly 15.6% versus the current price, while the forward PE of 11.2 suggests cheapness relative to earnings growth. Strong operating margins (gross 55.7%, operating 48%, profit 31.6%) and robust free cash flow ($1.30 billion) underpin a sustainable dividend yield of 0.97% and a modest payout ratio of 17%. However, the company faces high 30‑day volatility (≈52%) and a beta above 1, reflecting sensitivity to commodity cycles and geopolitical exposure across Latin America. Overall, the blend of solid fundamentals, attractive valuation, and momentum supports a positive outlook.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Bullish MACD and price above key moving averages
  • Strong Q1 earnings momentum and 12% price rally
  • Increasing volume supporting upward bias

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Potential price consolidation near resistance at $88
  • Continued exposure to commodity volatility
  • Ongoing capital investment plans that may cap short‑term earnings

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF implied upside of ~15% and cheap forward PE
  • Sustainable dividend policy with strong free cash flow
  • Diversified multi‑country asset base offering long‑term growth

Key Metrics & Analysis

Financial Health

Revenue Growth49.30%
Profit Margin31.65%
P/E Ratio20.1
ROE20.80%
ROA10.61%
Debt/Equity11.49
P/B Ratio3.8
Op. Cash FlowCA$1.7B
Free Cash FlowCA$1.3B

Technical Analysis

TrendNeutral
RSI68.4
SupportCA$68.76
ResistanceCA$88.04
MA 20CA$76.50
MA 50CA$76.55
MA 200CA$64.57
MACDBullish
VolumeIncreasing
Fear & Greed Index89.38

Valuation

Fair ValueCA$114.16
Target PriceCA$101.10
Upside/Downside15.65%
GradeUndervalued
TypeBlend
Dividend Yield0.97%

Risk Assessment

Beta1.15
Volatility51.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.